SLN - Silence Therapeutics PLC Profit before interest, taxes and amortization
Silence Therapeutics is implementing toxic substance filtration to comply with ESG standards. The EBITDA financial metric serves as a daily scanner of cash health, and its value is currently fixed at 0.00. Partnerships with pharma behemoths ensure a steady inflow of funds, although geopolitical tensions and patent risks create uncertainty regarding the company's intellectual property protection.
Silence Therapeutics plc (SLN) - metric breakdowns and financial figures
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization data:
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio Silence Therapeutics|SLN - Long-Term Debt to Capital|Current Liabilities to Capital Silence Therapeutics PLC|SLN - Company Debts|Debt to Net Assets Ratio Silence Therapeutics|SLN - Company Long-Term Debts|Company Short-Term Debts Silence Therapeutics|Critical Liquidity Ratio silence-therapeutics.com
- earnings and market ratios statistics:
SLN - Net Profit|Expected Net Profit Silence Therapeutics|SLN - Price to Earnings Ratio|Forward P/E Multiple silence-therapeutics.com|SLN - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Silence Therapeutics|SLN - Operating profit EBITDA|Net earnings per share for the last four quarters Silence Therapeutics|SLN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months silence-therapeutics.com|SLN - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Silence Therapeutics
Analysis of all company metrics:Silence Therapeutics Corp
Absolute operating profit measures the actual volume of cash generated by core production, neutralizing timing gaps between quarterly reports. An EBITDA cash flow analysis allows investors to promptly identify financial risks by assessing the monetization efficiency of siRNA drugs developed by Silence Therapeutics (SLN) through strategic partnerships with global pharmaceutical behemoths to accelerate the market launch of innovations.
Who Silence Therapeutics competes with
TEM - Operating profit before deduction of amortization|Qiagen N.V. - Operating profit EBITDA|Profit before interest, taxes and amortization ionispharma.com|RGEN (Repligen) - Operating profit before deduction of amortization|Avidity Biosciences Inc - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization CRSP|WGS (GeneDx Corp) - Company profit before taxes, interest and amortization|Operating profit EBITDA RARE|BEAM (beamtx.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA SRPT (Sarepta)|Twist Bioscience Inc (TWST) - Profit before interest, taxes and amortization|TXG - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization NTLA (Intellia Corp)|STOK: Operating profit EBITDA|biolifesolutions.com (BLFS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Wave Life Sciences Ltd.|Maze Therapeutics, Inc. - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA SION|PRME - Profit before interest, taxes and amortization|Taysha Gene Therapies - Operating profit before deduction of amortization|Operating profit EBITDA uniqure.com QURE|MGTX: Operating profit before deduction of amortization|REGENXBIO Inc - Company profit before taxes, interest and amortization|SLDB: Operating profit EBITDA|OCGN - Operating income before deduction of amortization|PACB (Pacific Biosciences) - Operating profit EBITDA|Operating profit before deduction of amortization benitec.com (BNTC)|Profit before payment of interest, taxes and amortization Design Therapeutics, Inc. (DSGN)|Operating income before deduction of amortization Rocket Pharma|Profit before payment of interest, taxes and amortization 4D Molecular Therapeutics Inc FDMT|Operating income before deduction of amortization Lexeo Therapeutics Inc. (LXEO)|KRRO - Profit before payment of interest, taxes and amortization|EDIT: Profit before payment of interest, taxes and amortization|proqr.com (PRQR) - Profit before payment of interest, taxes and amortization|Operating profit before amortization CDXS|SGMO (Sangamo) - Operating profit EBITDA|Operating profit before amortization NAUT (Nautilus Biotechnology Inc)|Profit before payment of interest, taxes and amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Operating profit before amortization|Operating profit EBITDA GBIO (Generation Bio)|Operating profit EBITDA Boundless Bio Inc. BOLD|XCUR - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Imunon, Inc. IMNN|PHIO: Operating profit EBITDA|MBIO - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization TransCode Therapeutics Inc.|Profit before payment of interest, taxes and amortization BNGO|Operating profit EBITDA APDN|BLUE - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization ImmunoPrecise Antibodies Ltd. IPA|OMGA: Operating profit before amortization|Singular Genomics - Operating profit EBITDA|Regulus Therapeutics, Inc. (RGLS) - Operating profit before deduction of amortization|SYRS: Operating profit EBITDA|Profit before interest, taxes and amortization Telesis Bio, Inc (TBIO)|Operating profit before deduction of amortization TCON|UBX: Income before deduction of interest, taxes and amortization
